Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026)

Sarepta Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $3.3 billion for Q1 2026.

• In Q1 2026, Assets Average fell 12.11% year-over-year to $3.3 billion; the TTM figure through Mar 2026 stood at $3.3 billion (down 12.11% YoY), while the FY2025 annual figure was $3.7 billion, up 1.18% from the prior year.
• Assets Average for Q1 2026 stood at $3.3 billion, down from $3.4 billion in the prior quarter.
• The five-year high for Assets Average was $3.8 billion in Q4 2024, with the low at $3.0 billion in Q2 2022.
• The 5-year median for Assets Average is $3.2 billion (2024), against an average of $3.3 billion.
• The sharpest annual moves came in 2024 and 2026: Assets Average gained 18.65% in 2024, then retreated 12.11% in 2026.
• Sarepta Therapeutics' Assets Average stood at $3.1 billion in 2022, then increased by 1.43% to $3.2 billion in 2023, then increased by 18.65% to $3.8 billion in 2024, then retreated by 9.52% to $3.4 billion in 2025, then dropped by 4.6% to $3.3 billion in 2026.
• Business Quant data shows SRPT's Assets Average at $3.3 billion in Q1 2026, $3.4 billion in Q4 2025, and $3.6 billion in Q3 2025.